I. What changes - news to watch this week

🇩🇪 Bavaria Shines at BIO-Europe 2024: A Hub of Biotech Innovation and Collaboration

Munich, Germany – BIO-Europe 2024, a conference with thousands of life sciences companies, investors, and research partners coming together to discuss the latest in biotechnology, pharmaceuticals, and biopharma finance, shed light on the Bavarian Biotech Cluster, and particularly the ecosystem in the Alpine Rim—including Switzerland and Austria.

Here are the 12 Bavarian companies that were presented in the conference:

1. 2bind: Leaders in biophysical analysis, offering advanced solutions in drug discovery.

2. Aurigon GmbH: Innovating in early-stage drug development with robust preclinical research.

3. Coriolis Pharma: Experts in biopharmaceutical formulation, ensuring the stability of advanced therapies.

4. Labor LS SE & Co. KG: Key player in GMP-compliant testing, critical for pharma quality assurance.

5. Minaris Regenerative Medicine: Pioneers in cell and gene therapy, advancing the personalized medicine frontier.

6. PolyQuant: Pushing the boundaries of protein quantification, enabling precise and powerful analytics.

7. PROTEROS biostructures GmbH: Structural biology innovators, guiding the future of precision medicine.

8. Staburo GmbH: Statistical experts in clinical trials, streamlining pathways for new therapy approvals.

9. Systasy Bioscience GmbH: Leaders in functional genomics, driving new possibilities in target identification.

10. Ingeeneon: Bioprocessing experts, optimizing therapy development at scale.

11. Trials24 GmbH (now part of SubjectWell, Inc.) – Revolutionizing patient recruitment and accelerating clinical trial enrollment.

12. WACKER: Providing forward-thinking biologics manufacturing solutions.

These standout Bavarian companies embodied innovation, demonstrating Germany’s ability to shape the future of global biotech.

Stay tuned for more developments as Bavaria continues to take charge of biotech innovation and collaboration!

Read more about the exit strategy of biotech companies here.

II. What never changes - timeless wisdom

On reading and writing

If you only read and don’t write, you are doing it wrong.

It is unnecessary to repeat the advantages of writing down your thoughts or journaling but to address the common challenges that prevent people from doing so. As far as my memory goes, I read a lot and wrote almost none when I was younger. I had the imagination to write down my thoughts, but I found it too much work or not worth the time. In hindsight, I was just scared and did not know where to start.

I also imagined writing a book recording my thoughts, maybe at 15. Not until I finished college and worked for a year did I first pick up Ulysses and start writing at 23. Did the meantime of eight years nurture my thoughts and make me good at writing? Absolutely not.

The interesting thing about writing is that you only get better by doing it more, not by daydreaming or reading tips online. But where do you start when you are an absolute beginner? It turns out, yes, the first ten pieces of your writing should be a POS, and you should accept that. This fact is largely dismissed and ignored by online experts who give tips and try to sell you writing courses to help you become a writer overnight. I don’t have a writing course to sell you, so I would tell you the one important tip about writing, start and write some craps.

Continue reading…

III. Book Quotes

Here are some book quotes for you to ponder over the weekend.

Thanks for reading,

— Anthony